Using Mobile Phone Short Message Service (SMS) Reminders to Enhance Appointment Attendance in DM Patients

February 14, 2017 updated by: The University of Hong Kong

Using Mobile Phone Short Message Service (SMS) Reminders to Enhance Type 2 Diabetes Mellitus Appointment Attendance in a Primary Care Clinic

A randomized controlled trial of patients with type 2 diabetes mellitus with multiple appointments into short message service group and control group. The attendance rate of these two groups of patients will be compared.

Study Overview

Detailed Description

The main objective of this study is to evaluate the appointment attendance rate using SMS reminder of nurses and allied health appointments for diabetic patients, when compared to conventional telephone reminder and no reminder. We also aim at determine the factors associated with appointment attendance. Finally, we will also survey patients' acceptance and satisfaction to the SMS service.

This is a single blind randomization study. It will be carried out in Ha Kwai Chung General Outpatient Clinic.

The primary outcome of this study is to evaluate the attendance rate of each individual doctor, nurses and allied health clinic appointments for diabetic patients, as well as their overall attendance rates:

  1. Diabetes Complication Screening Clinic (OPAS DMCS/RDNA)
  2. Diabetes Nurse Intervention Clinic (OPAS DMIC/RDNI)
  3. DM nurse group (OPAS RDNG)
  4. Dietitian Counselling (OPAS DC/DG)
  5. Physiotherapy (OPAS PTC/PTG)
  6. Diabetes Doctor Session (OPAS RDR)
  7. Retino photo Assessment (OPAS RDO)
  8. Blood taking appointment (OPAS LABT)

The secondary outcomes are:

  • Acceptance Rate of SMS Reminder Vs Telephone Reminder Vs no reminder
  • Factors associated with acceptance of SMS

    1. Personal Parameters: Age, sex, educational level, occupation, mobile phone models, Habit of using mobile phone service
    2. Disease Parameters: Number and types of comorbidity, disease control (by biochemical markers)
    3. Quality of Life (by SF-6D)
  • Reported adverse effects of the reminder system
  • Chang in biochemical markers (BMI, HbA1c, LDL-c level) 6-9 months later

Subjects who agreed to participate in this study will first receive a survey on the acceptance of SMS service. For those agree to receive SMS reminder, they will be randomized to:

  1. an SMS remind them to come for scheduled clinic appointment 24-72 hours before, or
  2. usual care with no reminder / telephone reminder.

Study Type

Interventional

Enrollment (Anticipated)

270

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Kwai Chung, Hong Kong, 000
        • Recruiting
        • Ha Kwai Chung General Outpatient Clinic
        • Contact:
        • Principal Investigator:
          • Man Chi Dao, M.B.B.S.
        • Sub-Investigator:
          • Sau Nga Fu, M.B.B.S.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • With diagnosis of type 2 diabetes
  • Have more than 1 clinic services appointment under RAMP-DM programme:

    (e.g. blood taking, diabetic nurse individual counselling, group education, diabetic complication screening, retinal photo assessment, dietician counselling, etc)

Exclusion Criteria:

  1. Cannot read or receive appointment schedule on mobile phone
  2. Do not speak Cantonese/English or read Chinese/English
  3. Mentally incapacitated
  4. Pregnant Women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SMS group
receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
No Intervention: Usual care group
Usual care, either telephone reminder or no reminder

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Attendance Rate of the scheduled clinic appointment
Time Frame: between booking time and appointment time, usually within 1 weeks to 16 weeks
Attendance Rate
between booking time and appointment time, usually within 1 weeks to 16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Man Chi Dao, M.B.B.S., Resident

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2016

Primary Completion (Anticipated)

June 30, 2017

Study Completion (Anticipated)

March 30, 2018

Study Registration Dates

First Submitted

February 14, 2017

First Submitted That Met QC Criteria

February 14, 2017

First Posted (Actual)

February 16, 2017

Study Record Updates

Last Update Posted (Actual)

February 16, 2017

Last Update Submitted That Met QC Criteria

February 14, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Mobile phone text message reminder

3
Subscribe